Business Wire

ENOSIUM-LIFE-SCI/OTIUM

5.3.2024 10:01:27 CET | Business Wire | Press release

Share
Enosium Life Science, a New Integrated Scientific Services Group for Biopharma Companies in Europe

Dr Antoine Amer, supported by Otium Capital, announced the creation of Enosium Life Science, a group poised to redefine services in the healthcare market by acquiring and combining best-in-class life science experts in Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305557434/en/

Enosium Life Science aims to be a key advisory and scientific services provider for pharmaceuticals, biotech and medtech firms from clinical development to commercialisation. Antoine Amer brings 20+ years of global pharmaceutical leadership experience in launching and growing healthcare innovations.

A Multi-Specialist European Group Dedicated to Life Sciences

Enosium Life Science combines local knowledge, scientific expertise, entrepreneurial agility, and international standards to address critical challenges facing pharmaceutical companies.

Enosium Life Science will implement a targeted acquisition strategy, focusing on service providers in: clinical research (CRO), regulatory affairs, market access, medical affairs, and marketing, to offer an end-to-end continuum of science-based services.

Antoine Amer, Enosium Life Science CEO, commented, "Our vision is to combine the best expertise across Europe, providing a unique and comprehensive range of scientific services to address growing complexities in the European healthcare ecosystem, which will enable faster and broader access to medical innovations for patients."

François Durvye, Otium Capital CEO, added, "Investing in Enosium Life Science demonstrates our commitment to supporting innovation and excellence in this key field. Led by Antoine Amer, Enosium Life Science aims to address the major challenges in medical innovations and improving patients’ health and quality of life."

About Enosium Life Science:

Enosium Life Science is an integrated group of scientific services for the European life sciences market. Providing comprehensive expertise from clinical development to commercialisation (clinical research, regulatory affairs, market access, medical affairs, marketing), Enosium Life Science is committed to becoming the partner-of-choice for healthcare industries, and to address the critical challenges facing pharma, biotech and medtech companies.

About Otium Capital:

Otium Capital is a major player in private investment in France with €1.5 billion in assets under management. Serving as the Family Office for French entrepreneur and founder of Smartbox Pierre-Edouard Stérin, Otium Capital invests across various domains. With significant experience in healthcare (Owkin, Hapni, Okomera, etc.) and expertise in buy-and-build strategies (Otium Leisure, Novavet, Otelium, Alfeor), Otium Capital is a key player in fostering innovation and growth.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240305557434/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Spatial Announces Release 2027 1.0 with New Enhancements Across CAD Modeling, Interoperability, Data Preparation, and Meshing17.11.2026 20:10:00 CET | Press release

Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced the availability of its 2027 1.0 Release. This latest release introduces new capabilities and enhancements across Spatial's 3D ACIS Modeler, CGM Modeler, 3D InterOp, Data Prep and CSM/CVM product lines. Designed to improve efficiency, flexibility and robustness across CAD modeling, interoperability, data preparation and simulation workflows, the release delivers enhanced geometry processing, expanded modeling capabilities, improved CAD translation and advances in mesh generation for a better workflow coverage. 3D ACIS Modeler Enhanced Blending (Filleting) The 3D ACIS Modeler introduces support for asymmetric fixed-width blends with a conic cross-section, providing users with finer control over smooth transitions between edges. This enhancement builds on the symmetric fixed-width blend with a conic cross-section capabilit

Global EV Alliance Survey: EV Drivers Identify Myths and Misconceptions as the Biggest Barrier to Adoption17.11.2026 19:00:00 CET | Press release

Myths and misconceptions about electric cars, from battery lifespan and fire risk to grid collapse, are the biggest barrier to EV adoption, according to respondents to the annual Global EV Driver Survey. The 2026 survey draws on responses from more than 29,500 EV drivers across 34 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117539716/en/ MYTHS. Battery lifespan (72%), fire risk (58%) and grid collapse (45%) top the list of EV myths reported by respondents to the 2026 Global EV Driver Survey, which gathered responses from more than 29,500 EV drivers across 34 countries. “The EV transition is not just an infrastructure or affordability challenge. It is also an information challenge. Outdated information and misconceptions continue to influence decisions long after the technology has moved on,” says Ellen Hiep, from the Steering Committee of the Global EV Alliance (GEVA). Myths the greatest barrier Asked to ide

TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer17.11.2026 18:04:00 CET | Press release

Seasoned biotech CFO with gene therapy, diagnostics, IPO and Wall Street experience joins the executive leadership team TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its next phase of growth. “I am delighted to welcome James to TreeFrog. James brings a valuable combination of biotech CFO and Wall Street experience that supports our ambitions to develop TreeFrog into a key enabling partner and drug developer in the regenerative medicines field,” said Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics. James contributes deep experience in corporate finance, capital markets and

Visa Report: AI-Enabled Fraud and Third-Party Attacks Are Scaling Worldwide17.11.2026 16:40:00 CET | Press release

Third-party incidents surged 62%, while Visa Scam Disruption identified more than $1.4 billion in potential fraud Fraud is becoming more automated, targeted and global as criminals use AI to exploit weak points across the payments ecosystem and target third-party providers that can provide access to multiple downstream payment organizations, according to the Visa (NYSE: V) Fall 2026 Biannual Threats Report released today during International Fraud Awareness Week. Developed by Visa Payment Ecosystem Risk and Control (PERC), the report examines threat activity observed between January and June 2026 and finds that AI is not creating entirely new categories of fraud. Instead, it is helping criminals that execute existing attacks faster, at greater scale, and with greater precision, while increasingly targeting third-party providers that can provide access to multiple downstream organizations at once. Although attack volumes increased in several areas, the report also found evidence that co

Sparxity Appoints former Cray CEO Peter Ungaro and Semiconductor Veteran Daniel Armbrust to its Advisory Board17.11.2026 16:00:00 CET | Press release

Appointments bring decades of leadership experience in supercomputing, semiconductor commercialization, and scaling advanced computing business Sparxity, a leader in sparse-native computing, today announced that Peter Ungaro, former President and CEO of Cray, Inc., and Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst, have joined its Advisory Board as independent members. Armbrust has been elected Chairman of the Advisory Board and Ungaro Deputy Chairman by their fellow board members. The appointments strengthen the company’s leadership as it scales its sparse-native computing technology for next-generation AI and high-performance computing (HPC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117761685/en/ From left to right, Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst and Peter Ungaro, former President and CEO of Cray, Inc. Peter Ungaro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye